Ophthalmic screening of patients receiving ketoprofen or flurbiprofen medication for inflammatory and degenerative joint diseases.
Twenty-seven patients with inflammatory and degenerative arthritis, who had been treated with either ketoprofen and flurbiprofen, for a period of up to twenty-four months, were examined for evidence of ocular toxicity. A practical method for examining the ocular structures and assessing visual function is described. A number of ophthalmic abnormalities were noted but these were related to previous or present eye disease or degeneration. It was considered that no ocular toxic sideeffects could be attributed to either drug during the period of treatment.
D000328:Adult; D000368:Aged; D000700:Analgesics / Q000009:adverse effects* / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy*; D001577:Benzophenones / Q000009:adverse effects*; D003315:Cornea / Q000187:drug effects; D005123:Eye / Q000187:drug effects*; D005260:Female; D005480:Flurbiprofen / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy*; D007660:Ketoprofen / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007908:Lens, Crystalline / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000009:adverse effects*; D012160:Retina / Q000187:drug effects; D013997:Time Factors; D014792:Visual Acuity / Q000187:drug effects
D000700:Analgesics; D001577:Benzophenones; D011422:Propionates; D005480:Flurbiprofen; D007660:Ketoprofen